Sonimodul website. Is it me?

[jeeves19]

I visited Sonimodul’s website last night. I have to say that I was pretty disappointed with the standard of presentation and information relayed! Considering the $$ they charge I thought it’d be a lot more professional, informative and swish. I learn a darn sight more from those of you who’ve been there in comparison to what they explain there 😕. Just saying. 🤔

[jimcaster]

I found their YouTube channel to be more informative, particularly the series of 8 lectures by Dr. Jeanmonod and those by our own lenamm.

youtube.com/channel/UCjynp4...

[jeeves19 in reply to jimcaster]

Been there Jim and while he seems like a really nice guy, I can’t hear what he’s saying half the time. 😂. I think a short course in making a YouTube vid is called for!

[rebtar in reply to jimcaster]

I don't see any videos there.

[lenamm]

If you didn't want it on the website - this paper is super informative sonimodul.ch/wp-content/upl...

[jeeves19 in reply to lenamm]

Thanks Lena 👍

[dwell]

I thought the same when I first visited the site, it's surprisingly amateurish and almost simplistic. It seems to reflect that they're a small family business, not a major medical institution. But maybe that's not a bad thing? Perhaps they are more focused on the neurosurgery than on the website!

[sharoncrayn]

On this forum. you have the "true" zealous believers, those who remain neutral and "wait and see", and those who question the validity of their case study results and whether they can be extrapolated to a large population. And many who can't afford it.

HU contains multiple discussions and thorough analysis of their case studies. both pro and con. Essentially attempts to ameliorate essential tremor. 300 known treatments.

"Marc Gallay (lead surgeon) currently works since 2015 as neurosurgeon at the Center for Focused Ultrasound Neurosurgery Sonimodul, Switzerland. He received his medical degree at the University of Zurich in 2008. His doctoral dissertation was obtained in 2009 at the University Hospital Zürich under the supervision of Dr. Anne Morel and Prof. Daniel Jeanmonod. There he further studied the monkey and human insular cortex as a post-doc fellow before training in neurosurgery at the Kantonsspital St.Gallen and at the University Hospital Geneva."

Publicaions

1.

Bilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson's Disease With 1-Year Follow-Up

Marc N. Gallay, David Moser, Anouk E. Magara, Fabio Haufler, Daniel Jeanmonod

Front Neurol. 2021; 12: 601153. Published online 2021 Feb 9. doi: 10.3389/fneur.2021.601153

PMCID: PMC7900542

ArticlePubReaderPDF–1.2MCite

Select item 7212452

2.

MR-Guided Focused Ultrasound Central Lateral Thalamotomy for Trigeminal Neuralgia. Single Center Experience

Marc N. Gallay, David Moser, Daniel Jeanmonod

Front Neurol. 2020; 11: 271. Published online 2020 Apr 17. doi: 10.3389/fneur.2020.00271

PMCID: PMC7212452

ArticlePubReaderPDF–645KCite

Select item 6971056

3.

MRgFUS Pallidothalamic Tractotomy for Chronic Therapy-Resistant Parkinson's Disease in 51 Consecutive Patients: Single Center Experience

Marc N. Gallay, David Moser, Franziska Rossi, Anouk E. Magara, Maja Strasser, Robert Bühler, Milek Kowalski, Payam Pourtehrani, Christian Dragalina, Christian Federau, Daniel Jeanmonod

Front Surg. 2019; 6: 76. Published online 2020 Jan 14. doi: 10.3389/fsurg.2019.00076

PMCID: PMC6971056

ArticlePubReaderPDF–3.0MCite

Select item 6533852

4.

Radiological and Thermal Dose Correlations in Pallidothalamic Tractotomy With MRgFUS

Marc N. Gallay, David Moser, Christian Federau, Daniel Jeanmonod

Front Surg. 2019; 6: 28. Published online 2019 May 17. doi: 10.3389/fsurg.2019.00028

PMCID: PMC6533852

ArticlePubReaderPDF–3.5MCite

Select item 6353787

5.

Anatomical and Technical Reappraisal of the Pallidothalamic Tractotomy With the Incisionless Transcranial MR-Guided Focused Ultrasound. A Technical Note

Marc N. Gallay, David Moser, Christian Federau, Daniel Jeanmonod

Front Surg. 2019; 6: 2. Published online 2019 Jan 24. doi: 10.3389/fsurg.2019.00002

PMCID: PMC6353787

ArticlePubReaderPDF–1.6MCite

Select item 4752806

6.

Incisionless transcranial MR-guided focused ultrasound in essential tremor: cerebellothalamic tractotomy

Marc N. Gallay, David Moser, Franziska Rossi, Payam Pourtehrani, Anouk E. Magara, Milek Kowalski, Alexander Arnold, Daniel Jeanmonod

J Ther Ultrasound. 2016; 4: 5. Published online 2016 Feb 13. doi: 10.1186/s40349-016-0049-8

PMCID: PMC4752806

ArticlePubReaderPDF–2.7MCite

Select item 2494572

7.

Human pallidothalamic and cerebellothalamic tracts: anatomical basis for functional stereotactic neurosurgery

Marc N. Gallay, Daniel Jeanmonod, Jian Liu, Anne Morel

Brain Struct Funct. 2008; 212(6): 443–463. Published online 2008 Jan 10. doi: 10.1007/s00429-007-0170-0

PMCID: PMC2494572

ArticlePubReaderPDF–1.6MCite

sharon

😇

[jeeves19 in reply to sharoncrayn]

Messaging you soon

[Trixiedee in reply to sharoncrayn]

Sharon I have never had a tremor and was treated at Sonimodul. They don’t only treat essential tremor. Surely you know that.

[sharoncrayn in reply to Trixiedee]

My sentence and its context was misleading in using the term essential tremor. I meant to say that in their reported case (51) study, The MRgFUS PTT intervention was most successful in "essentially" alleviating tremors on the operated side.

"Patients reported an 88% mean tremor relief and 82% mean global symptom relief on the operated side and 69% mean global symptom improvement for the whole body. There was no significant change of cognitive functions. "

Unfortunately, one year UPDRS evaluations were only done on 21-26 participants and the non-operated side showed minimal reduction in tremor. (leading to the follow up study)

Sorry for the confusing wording.

sharon

[MBAnderson in reply to sharoncrayn]

Thank you, Dr. Crayon.

[sharoncrayn in reply to MBAnderson]

Is it an irreversible intervention? (Not a NYTimes conspiracy theory).

Citations you should read carefully and understand:

Safety and accuracy of incisionless transcranial MR-guided focused ultrasound functional neurosurgery: single-center experience with 253 targets in 180 treatments

Marc N Gallay, David Moser, Daniel Jeanmonod

Abstract

OBJECTIVE Since the first clinical application of the incisionless magnetic resonance-guided focused ultrasound (MRgFUS) technology only small series of patients have been reported, and thus only extrapolations of the procedure-related risks could be offered. In this study, the authors analyze side-effects and targeting accuracy in 180 consecutive treatments with MRgFUS for chronic therapy-resistant idiopathic Parkinson's disease (PD), essential tremor (ET), cerebellar tremor (CT), and neuropathic pain (NP), all performed in their dedicated center.

METHODS A total of 180 treatments with MRgFUS for chronic therapy-resistant idiopathic PD, ET, CT, and NP were prospectively assessed for side-effects and targeting accuracy. Monitoring for later side-effects was continued for at least 3 months after the procedure in all but 1 case (0.6%); in that single case, the patient was lost to follow-up after an uneventful early postoperative course. The surgical targets were the pallidothalamic tract (pallidothalamic tractotomy, n = 105), the cerebellothalamic tract (cerebellothalamic tractotomy, n = 50), the central lateral nucleus (central lateral thalamotomy, n = 84), the centrum medianum (centrum medianum thalamotomy, n = 12), and the globus pallidus (pallidotomy, n = 2). Cognitive testing was performed before, 1-2 days after, and 1 year after the procedure. The Mini-Mental State Examination (MMSE) was used for the first 29 cases and was then replaced by the Montreal Cognitive Assessment (MoCA). Lesion reconstruction and measurement of targeting accuracy were done on 2-day posttreatment MR images for each performed target. To determine targeting accuracy measurement, 234 out of the 253 lesions depicted in the 2-day postoperative MR examination could be 3D-reconstructed.

RESULTS The mean MoCA score was slightly improved 2 days postoperatively (p = 0.002) and remained stable at 1-year follow-up (p = 0.03). The mean MMSE score was also slightly improved 2 days postoperatively and at 1-year follow-up, but the improvement was not statistically significant (p = 0.06 and p = 0.2, respectively). The mean (± SD) accuracy was 0.32 ± 0.29 mm, 0.29 ± 0.28 mm, and 0.44 ± 0.39 mm for the mediolateral, anteroposterior, and dorsoventral dimensions, respectively. The mean 3D accuracy was 0.73 ± 0.39 mm. As to side-effects, 14 events over 180 treatments were documented. They were classified into procedure-related (n = 4, 2.2%), effect on neighboring structures (n = 3, 1.7%), and disease-related (n = 7, 3.9%). There was no bleeding.

_______________________________________________________________________

MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: anatomical target reappraisal and clinical results

Marc N Gallay, David Moser, Daniel Jeanmonod

Abstract

Objective: In addition to the well-recognized ventral intermediate nucleus (Vim) thalamotomy for the treatment of chronic therapy-resistant essential tremor (ET), an alternative approach targeting the posterior part of the subthalamus was proposed in the 1960s and early 1970s and then was reactualized as cerebellothalamic tractotomy (CTT) with the advent of MR-guided focused ultrasound (MRgFUS) surgery. The goal of this study was to improve target coverage and thus efficacy (i.e., tremor control and its consistency). The authors undertook a histological reappraisal of the CTT target and proposed a targeting strategy of the MRgFUS CTT based on 1) the MR visualization of the center of the red nucleus and 2) the application of preplanned target subunits realized with short sonications under thermal dose control. This study was aimed at demonstrating the efficacy and risk profile of this approach against chronic therapy-resistant ET.

Methods: Ten consecutive patients suffering from chronic therapy-resistant ET benefited from a unilateral MRgFUS CTT and were followed over the course of 1 year. Primary endpoints were subjective tremor relief, Clinical Rating Scale for Tremor (CRST) score, activities of daily living (ADL) score, and the hand function (HF) scores HF16 and HF32. Histological reappraisal of the target led the authors to propose a standardized targeting protocol for MRgFUS CTT. Thermal doses for 18 and 240 cumulative equivalent minutes at 43°C were calculated and correlated with intraoperative and 2 days postoperative T2-weighted MR images.

Results: The mean ± SD for the baseline CRST score was 48 ± 12; the score was 16 ± 7 at 3 months, and 17 ± 8 at 1 year. The mean tremor relief rated by the patients for the operated side was 95% after 2 days, 96% at 3 months, and 93% at 1 year. The mean HF16 was 11.0 ± 2.1 at baseline, 0.7 ± 0.7 at 3 months, and 0.8 ± 0.9 at 1 year (93% mean reduction). The minimum reduction for the HF16 at 1 year was 78%. There was a 51% reduction of the mean ADL score at 1 year. There was no bleeding or infection. Gait difficulties, only detectable on tandem gait, were increased in 3 patients and reduced in 2 patients at 1 year. There was no dysarthria.

Conclusions: The authors' results suggest that MRgFUS CTT is a very effective treatment option for therapy-resistant ET.

CLINICAL TRIALS - HARVARD

ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson’s Disease

PI: G. Rees Cosgrove, MD

Global Registry: ExAblate 4000 Transcranial MR Guided Focused Ultrasound (TcMRgFUS) of Neurological Disorders

PI: G. Rees Cosgrove, MD

A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson’s Disease with Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System

PI: G. Rees Cosgrove, MD

Notable Papers on FUS re ET

Iorio-Morin C, Hodaie M, Lozano AM. Adoption of focused ultrasound thalamotomy for essential tremor: why so much fuss about FUS? J Neurol Neurosurg Psychiatry. 2021 Feb 9:jnnp-2020-324061. doi: 10.1136/jnnp-2020-324061.

Chang KW, Rachmilevitch I, Chang WS, Jung HH, Zadicario E, Prus O, Chang JW. Safety and Efficacy of Magnetic Resonance-Guided Focused Ultrasound Surgery With Autofocusing Echo Imaging. Front Neurosci. 2021 Jan 12;14:592763. doi: 10.3389/fnins.2020.592763. eCollection 2020.

Abe K, Horisawa S, Yamaguchi T, Hori H, Yamada K, Kondo K, Furukawa H, Kamada H, Kishima H, Oshino S, Mochizuki H, Kanemoto M, Hirabayashi H, Fukutome K, Ohnishi H, Igase K, Matsubara I, Ohnishi T, Sadamoto K, Taira T. Focused Ultrasound Thalamotomy for Refractory Essential Tremor: A Japanese Multicenter Single-Arm Study. Neurosurgery. 2021 Jan 19:nyaa536. doi: 10.1093/neuros/nyaa536.

Osterholt T, McGurrin P, Bedard P, Horovitz S, Ehrlich D, Haubenberger D. Thalamic Tremor Following Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor. Mov Disord Clin Pract. 2020 Oct 27;8(1):139-141. doi: 10.1002/mdc3.13097. eCollection 2021 Jan.

Giordano M, Caccavella VM, Zaed I, Foglia Manzillo L, Montano N, Olivi A, Polli FM. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1270-1278. doi: 10.1136/jnnp-2020-323216. Epub 2020 Oct 14.

De Vloo P, Milosevic L, Gramer RM, Dallapiazza RF, Lee DJ, Fasano A, Hutchison WD, Lozano AM, Schwartz ML, Kalia SK. Microelectrode Recording and Radiofrequency Thalamotomy following Focused Ultrasound Thalamotomy. Stereotact Funct Neurosurg. 2020 Sep 16:1-4. doi: 10.1159/000510109.

McDannold NJ, White PJ, Cosgrove GR. MRI-based thermal dosimetry based on single-slice imaging during focused ultrasound thalamotomy. Phys Med Biol. 2020 Sep 11. doi: 10.1088/1361-6560/abb7c4.

Jones RM, Huang Y, Meng Y, Scantlebury N, Schwartz ML, Lipsman N, Hynynen K. Echo-Focusing in Transcranial Focused Ultrasound Thalamotomy for Essential Tremor: A Feasibility Study. Mov Disord. 2020 Aug 20. doi: 10.1002/mds.28226.

Su JH, Choi EY, Tourdias T, Saranathan M, Halpern CH, Henderson JM, Pauly KB, Ghanouni P, Rutt BK. Improved Vim targeting for focused ultrasound ablation treatment of essential tremor: A probabilistic and patient-specific approach. Hum Brain Mapp. 2020 Aug 6. doi: 10.1002/hbm.25157.

Saluja S, Barbosa DAN, Parker JJ, Huang Y, Jensen MR, Ngo V, Santini VE, Pauly KB, Ghanouni P, McNab JA, Halpern CH. Case Report on Deep Brain Stimulation Rescue After Suboptimal MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor: A Tractography-Based Investigation. Front Hum Neurosci. 2020 Jun 26;14:191. doi: 10.3389/fnhum.2020.00191. eCollection 2020.

Kapadia AN, Elias GJB, Boutet A, Germann J, Pancholi A, Chu P, Zhong J, Fasano A, Munhoz R, Chow C, Kucharczyk W, Schwartz ML, Hodaie M, Lozano AM. Multimodal MRI for MRgFUS in essential tremor: post-treatment radiological markers of clinical outcome. J Neurol Neurosurg Psychiatry. 2020 Jul 10:jnnp-2020-322745. doi: 10.1136/jnnp-2020-322745.

Ito H, Yamamoto K, Fukutake S, Odo T, Kamei T. Two-year Follow-up Results of Magnetic Resonance Imaging-guided Focused Ultrasound Unilateral Thalamotomy for Medication-refractory Essential Tremor. Intern Med. 2020 Jul 7. doi: 10.2169/internalmedicine.4360-19.

Yamamoto K, Ito H, Fukutake S, Odo T, Kamei T, Yamaguchi T, Taira T. Movement during focused ultrasound therapy caused by an unstable magnetic resonance table: case report. J Neurosurg. 2020 Jul 3:1-4. doi: 10.3171/2020.4.JNS20219.

Buch VP, McShane BJ, Beatson N, Yang A, Blanke A, Tilden D, Korn M, Chaibainou H, Ramayya A, Wombacher K, Maier S, Marashlian T, Wolf R, Baltuch GH. Focused Ultrasound Thalamotomy with Dentato-Rubro-Thalamic Tractography in Patients with Spinal Cord Stimulators and Cardiac Pacemakers. Stereotact Funct Neurosurg. 2020 May 13:1-7. doi: 10.1159/000507031.

Fukutome K, Kuga Y, Ohnishi H, Hirabayashi H, Nakase H. What factors impact the clinical outcome of magnetic resonance imaging guided focused ultrasound thalamotomy for essential tremor? J Neurosurg. 2020 May 1:1-6. doi: 10.3171/2020.2.JNS192814.

Chapman M, Park A, Schwartz M, Tarshis J. Anesthesia considerations of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor: a case series. Can J Anaesth. 2020 Apr 14. doi: 10.1007/s12630-020-01644-1.

Bruno F, Catalucci A, Arrigoni F, Sucapane P, Cerone D, Cerrone P, Ricci A, Marini C, Masciocchi C. An experience-based review of HIFU in functional interventional neuroradiology: transcranial MRgFUS thalamotomy for treatment of tremor. Radiol Med. 2020 Apr 7. doi: 10.1007/s11547-020-01186-y.

Paff M, Boutet A, Neudorfer C, Elias GJB, Germann J, Loh A, Kucharczyk W, Fasano A, Schwartz ML, Lozano AM. Magnetic Resonance-Guided Focused Ultrasound Thalamotomy to Treat Essential Tremor in Nonagenarians. Stereotact Funct Neurosurg. 2020 Mar 30:1-5. doi: 10.1159/000506817.

Gallay MN, Moser D, Jeanmonod D. MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: anatomical target reappraisal and clinical results. J Neurosurg. 2020 Feb 7:1-10. doi: 10.3171/2019.12.JNS192219.

Parras O, Domínguez P, Tomás-Biosca A, Guridi J. The role of tractography in the localization of the Vim nucleus of the thalamus and the dentato-rubro-thalamic tract for the treatment of tremor. Neurologia. 2020 Jan 5. pii: S0213-4853(19)30131-8. doi: 10.1016/j.nrl.2019.09.006. [Epub ahead of print] Review. English, Spanish.

sharon

[MBAnderson in reply to sharoncrayn]

"Citations you should read carefully and understand:" More like, 'citations not to bother with because none are on point.'

I don't see where any of the studies you cite are relevant to the PTT procedure with the possible exception of the one that explores various thicknesses of a person's skull. Certainly, all those that are thalamotomies for essential tremor aren't, so what is the point of listing them all? Even the one by Dr. J is about a different procedure.

I have always maintained that anyone contemplating the FUS PTT should read everything they can about it especially those descriptions by people have had a negative outcome, but none of the material you provided above will inform a person about the PTT procedure.

[sharoncrayn in reply to MBAnderson]

I agree with you....very little is available on FUS PTT, (almost nothing specific to "pallidothalamic") which was my point in providing the info which you conveniently missed..

So, to help people without your obvious bias, Provide your list of citations/papers beyond the Swiss (sonimodul)!

I could only find one (again out of Switzerland).

First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease.

Magara A1, Bühler R2, Moser D3, Kowalski M4, Pourtehrani P5, Jeanmonod D3

Author information

Journal of Therapeutic Ultrasound, 31 May 2014, 2:11

DOI: 10.1186/2050-5736-2-11 PMID: 25512869 PMCID: PMC4266014

Free to read & use

Share this article Share with emailShare with twitterShare with linkedinShare with facebook

Abstract

Background

Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies.

Methods

Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion.

Results

The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively.

Conclusions

This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect.

sharon

[MBAnderson in reply to sharoncrayn]

“So, to help people without your obvious bias…”

What you are saying, essentially, is that I, and by extension, everyone else on this forum, do not have enough scientific evidence to justify the decision I, and a handful of others, have made simply highlights, once again, the difference between you having the luxury of making this an intellectual decision, whereas I don't.

I try not to play the “easy for you to say, you don’t have PD” card, but in this case, it explains the difference. Yes, it (PTT) is irreversible, but so is the progression and we either let it take us down or we take a risk and try something that doesn’t as yet meet your and the FDA standard of proof.

In other words, it should be clear to everyone, especially now that PTT trials are about to get underway, that the PTT target used in Switzerland and technique of MRg FUS will be approved by the FDA thereby meeting your standard for us to justify this decision.

I'm just ahead of you -- and the FDA.

[Godiv]

It looks like the down and dirty so to speak. Maybe it’s written for all audiences? But I know, it seems like a very light treatment for what they charge and the seriousness of the whole thing. And they had the dreaded “page not found” on the website, which always irks my cranky self. Fix it fix it! But it does sound like they have better information elsewhere.

[Trixiedee]

I don’t think they need to give it the hard sell as they have no shortage of patients. I’d be more suspicious if their website was really slick.

[jeeves19 in reply to Trixiedee]

Good point. How are things btw?

[Trixiedee in reply to jeeves19]

Pretty good as far as my FUS results go. I saw my neurologist last week who was really impressed and is going to mention my results to Kings College Hospital where he works. I’m struggling emotionally with the whole pandemic situation though and this eternal winter.

[jeeves19 in reply to Trixiedee]

I’m really chuffed that the neuro is impressed and is mentioning it in larger neurological groups. We need to get the message out there and thank you for having the bottle to undergo what is still pioneering stuff. As regards the winter: things can’t be as good on the sunny south coast as I’m led to believe.😕. Easter was fab ‘up north’ with daily blue skies (if a little cold 🥶)

[Trixiedee in reply to jeeves19]

It would have taken more courage not to have FUS. My life was so incredibly limited before treatment - I was either off and virtually paralysed or wildly dyskinetic.

[ConnieD in reply to Trixiedee]

Has stress had any impact on the improvements you had from surgery?

[Trixiedee in reply to ConnieD]

No I don’t think stress has had any impact. I’ve had a very stressful time since the treatment. Maybe I’d be completely healed without the stress!

[ConnieD in reply to Trixiedee]

So happy you’re doing so well!

[Trixiedee in reply to ConnieD]

Thanks 😊

[Motherfather in reply to Trixiedee]

come to perth west australia trixiedee here we have beautiful weather all year, winter is pretty good as well and we have no pandemic..regards..john.

[Trixiedee in reply to Motherfather]

I’d love to visit Australia but I’d have to bring my kids and couldn’t afford 3 flights. There’s an incredible acupuncturist in Perth.

[Astra7 in reply to Trixiedee]

I live in Perth. Who is the acupuncturist? Might be worth a try!

[Trixiedee in reply to Astra7]

His name is Roy Jenzen.

[jeeves19]

Yes I remember some of your old posts and felt for you. Enjoy your new freedom. Are you in touch with that lady who made the film about going to Switzerland? I forget her name. If so, how is she 4 years on?

[Trixiedee in reply to jeeves19]

Yes I’m vaguely in touch with her. She’s doing well, no return of symptoms altogether she had a bilateral treatment on the same day and her speech was affected. That hasn’t improved but they only do bilateral treatments at least a year apart now. She thinks it was a worthwhile compromise.

[jeeves19 in reply to Trixiedee]

Thanks for that 🙏😊

[ion_ion]

This is a new trend for the WEB sites: to be very simple. Also it is more commercial than scientific.